Business
PDS Announces Release of PDS0101 Abstract
PDS Announces Release of PDS0101 Abstract.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3449Z\n NetScientific PLC\n 20 May 2021\n \n \n \n \n NetScientific plc\n \n \n (\"NetScientific\", the \"Group\" or the \"Company\")\n \n \n \n \n \n PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting\n \n \n \n \n \n \n London, UK - 20 May 2021\n \n - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB) today announced publication of abstract #2501 by the American Society of Clinical Oncology (ASCO). The abstract summarizing interim data from the National Cancer Institute (NCI)-led phase 2 trial has been accepted for oral presentation at the 2021 ASCO Annual Meeting taking place June 4-8. The presentation, scheduled for June 7, is expected to include results from a larger sample than the 14 patients included in the abstract.\n \n \n \n \n \n Additional data highlights from abstract #2501 include:\n \n \n \n \n \n · \n An overall objective response rate of 71% (10/14) in patients with refractory HPV16-associated cancers\n \n \n o \n 1 complete response (anal cancer)\n \n \n o \n 9 partial responses (3 cervical cancer, 2 vulvar/vaginal cancer, 2 anal cancer, 2 oropharyngeal cancer)\n \n \n · \n 90% of these of these responses are ongoing after a median 5 months of follow up (9/10)\n \n \n \n \n \n \n Dr. Lauren Wood, Chief Medical Officer of PDS Biotech commented:\n \n \n \"The achievement of a 71% objective response rate in a difficult to treat patient population continues to strengthen the evidence of our novel Versamune® platform's potential ability to induce high levels of tumor-specific CD8+ killer T-cells that attack the cancer resulting in strong synergy with Bintrafusp alfa and NHS-IL12, thus leading to effective tumor regression.\n \n \n \n \n \n \n \"The initial data solidifies our belief that PDS0101's published preclinical efficacy, when combined with these two immune-modulating agents, demonstrates the potential to significantly improve clinical outcomes for patients with advanced, refractory HPV-associated cancers who have limited treatment options.\"\n \n \n \n \n \n \n Dr. Ilian Il...